AbCellera Biologics (ABCL) EBT Margin (2020 - 2026)
AbCellera Biologics (ABCL) reported EBT Margin of 595.75% for Q1 2026, up 65534.0% on a YoY basis from N/an in Q1 2025, and down 1270.4% quarter-over-quarter from 43.47% in Q4 2025.
AbCellera Biologics (ABCL) EBT Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics has reported EBT Margin for 7 years, with the latest figure at 595.75% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 65534.0% year-over-year to 595.75%; the trailing twelve-month figure through Mar 2026 stood at 219.86% (up 69137.0% YoY), and the FY2025 full-year result was 236.39%, up 45863.0% from the prior year.
- EBT Margin for Q1 2026 stood at 595.75%, down from 43.47% in the prior quarter.
- The five-year high for EBT Margin was 72.91% in Q1 2022, with the low at 1251.1% in Q1 2025.
- Historically, EBT Margin has averaged 458.1% across 5 years, with a median of 429.45% in 2024.
- The largest YoY upside for EBT Margin was 88383 bps in 2025 against a maximum downside of 82165 bps in 2025.
- AbCellera Biologics' EBT Margin stood at 145.8% in 2022, then tumbled by 263 bps to 529.49% in 2023, then sank by 75 bps to 927.31% in 2024, then jumped by 95 bps to 43.47% in 2025, then sank by 1270 bps to 595.75% in 2026.
- The last three EBT Margin figures came in at 595.75% (Q1 2026), 43.47% (Q4 2025), and 767.93% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | AbCellera Biologics | 1.55 Bn | 1.44 Bn | - | -595.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -595.75% |
| Dec 31, 2025 | -43.47% |
| Sep 30, 2025 | -767.93% |
| Jun 30, 2025 | -212.74% |
| Mar 31, 2025 | -1,251.10% |
| Dec 31, 2024 | -927.31% |
| Sep 30, 2024 | -962.53% |
| Jun 30, 2024 | -658.02% |
| Mar 31, 2024 | -429.45% |
| Dec 31, 2023 | -529.49% |
| Sep 30, 2023 | -595.18% |
| Jun 30, 2023 | -377.92% |
| Mar 31, 2023 | -394.91% |
| Dec 31, 2022 | -145.80% |
| Sep 30, 2022 | 45.95% |
| Jun 30, 2022 | -15.00% |
| Mar 31, 2022 | 72.91% |
| Dec 31, 2021 | 60.80% |
| Sep 30, 2021 | -453.38% |
| Jun 30, 2021 | -7.50% |